fda statement bpc 157 not approved for human use panel backs compounded BPC-157, KPV peptides in win RFK Jr FDA may take an important

These findings underscore why source verification matters for peptide therapy

It is under investigation in preclinical and clinical studies on overweight, obesity, and metabolic disorders, where researchers have examined its effects on body weight and energy intake, including when combined with GLP 1 receptor agonists such as semaglutide, but it is not an approved therapy

In addition, it appears to modulate various molecular pathways that are involved in inflammation, immune function, and nerve regeneration

The reduction in inflammation directly improves symptoms such as abdominal pain, bloating, and diarrhea, while promoting overall gut barrier integrity and digestive health